Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378205 | 0.87 | ABCB1 (0.47) | SLC6A2SLC6A3SLC6A4TSHRHTT | |
| SCHEMBL9129333 | 0.87 | CHRNB2 (0.61) | SLC6A2SLC6A3SLC6A4KMT2AMEN1 | |
| SCHEMBL8658086 | 0.85 | KMT2A (0.51) | SLC6A2SLC6A3KMT2AMEN1CYP1A2 | |
| SCHEMBL6205189 | 0.82 | CNR2 (0.48) | SLC6A2SLC6A3SLC6A4KMT2AMEN1 | |
| SCHEMBL10784028 | 0.79 | TSHR (0.52) | SLC6A2SLC6A3SLC6A4TSHRSLC1A3 | |
| SCHEMBL7771215 | 0.79 | CA1 (0.44) | SLC6A2SLC6A3SLC6A4TSHRKMT2A | |
| SCHEMBL994682 | 0.78 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4TSHRSLC1A3 | |
| SCHEMBL10431978 | 0.77 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4TSHRCYP1A2 | |
| SCHEMBL11100946 | 0.77 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4TSHRSLC1A3 | |
| SCHEMBL29277743 | 0.77 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4TSHRSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | claimed |
| US-4568490-A | REDUCTIVE CONDENSATION WITH A CARBONYL COMPOUND | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1986-02-04 | — | — | US | claimed |
| EP-0023773-A1 | Process for preparing pyrazolo(1,5-c)-quinazoline derivatives and novel intermediates | E.R. Squibb & Sons, Inc. (US) | 1981-02-11 | — | — | EP | claimed |
| JP-59175497-A | — | — | None | — | — | JP | disclosed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| EP-4103186-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163633-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-30 | — | — | US | disclosed |
| US-9872919-B2 | Prodrugs for selective anticancer therapy | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-01-23 | — | — | US | disclosed |
| US-9556105-B2 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160046648-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
| US-5962180-A | COMPRISING (A) A COPOLYMER COMPRISING RECURRING UNITS OF A P-HYDROXYSTYRENE UNIT AND A STYRENE UNIT HAVING AN ACETAL GROUP OR A KETAL GROUP AT THE P-POSITION, (B) A COPOLYMER COMPRISING RECURRING UNITS OF A T-BUTYL (METH)ACRYLATE UNIT | JSR CORPORATION (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5741438-A | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as an effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0793144-A2 | Radiation sensitive composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| US-5541163-A | HYPOTENSIVE AGENTS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-07-30 | — | — | US | disclosed |
| US-4568490-A | REDUCTIVE CONDENSATION WITH A CARBONYL COMPOUND | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1986-02-04 | — | — | US | disclosed |
| US-4537880-A | Aminopropylaminobleomycin derivatives and process for preparation thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-08-27 | — | — | US | disclosed |
| JP-S59175497-A | NOVEL AMINOPROPYLAMINOBLEOMYCIN DERIVATIVE AND ITS PREPARATION | MICROBIAL CHEM RES FOUND | 1984-10-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | SLC6A2 768/4885SLC6A3 55/4885SLC6A4 198/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | SLC6A2 4650/4885SLC6A3 4748/4885SLC6A4 4556/4885 |
| US-20160046648-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | SLC6A2 768/4885SLC6A3 55/4885SLC6A4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.